Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15647175 | 0.93 | NAMPT (0.60) | NAMPTCYP3A4CYP2C9CYP2C19DDR1 | |
| SCHEMBL5019744 | 0.90 | NAMPT (0.49) | NAMPTCYP3A4CYP2C9CYP2C19KCNQ3 | |
| SCHEMBL5019732 | 0.88 | NAMPT (0.61) | NAMPTCYP3A4CYP2C9CYP2C19ELANE | |
| SCHEMBL5019846 | 0.88 | NAMPT (0.49) | NAMPTCYP3A4CYP2C9CYP2C19DDR1 | |
| SCHEMBL15647268 | 0.87 | DDR1 (0.50) | NAMPTCYP3A4CYP2C9CYP2C19DDR1 | |
| SCHEMBL5019840 | 0.84 | KCNQ3 (0.59) | NAMPTCYP3A4CYP2C9CYP2C19KCNQ3 | |
| SCHEMBL15645757 | 0.83 | NAMPT (0.57) | NAMPTCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15646386 | 0.83 | CFTR (0.46) | NAMPTCYP3A4CYP2C9CYP2C19DDR1 | |
| SCHEMBL15681450 | 0.82 | DDR1 (0.43) | NAMPTCYP3A4CYP2C9CYP2C19DDR1 | |
| SCHEMBL15646063 | 0.81 | NAMPT (0.55) | NAMPTCYP3A4CYP2C9CYP2C19MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1S, KCNN4 | NAMPT 4652/4885CYP3A4 322/4885CYP2C9 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.